title: Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy.
abstract: The expression of connexin43, the primary gap-junction constituent of glial cells, was evaluated at the messenger RNA and protein levels in different grades of astrocytoma to investigate the relevance of gap junctions in herpes simplex virus-thymidine kinase (HSV-tk)-mediated gene therapy of brain tumors. Transduction of the retroviral-mediated HSV-tk gene into tumor cells with subsequent administration of ganciclovir has recently been used as an experimental therapeutic strategy for treatment of brain tumors. One aspect of this approach is the bystander effect, which augments the efficacy of this therapeutic approach. Glioblastoma cells with minimum levels of connexin43 protein were transfected with a connexin43 complementary DNA. These cells manifested a marked increase in the in vitro bystander effect, supporting the contention that the in vitro bystander effect is a consequence of metabolic cooperation between cells mediated by gap junctions. To assess relative levels of gap-junction protein expression in the relevant tumor type, we examined primary astrocytomas, primary astrocytoma cell cultures, and glioblastoma cell lines. Although most astrocytoma tumor samples expressed connexin43, they differed in the level of expression, with the greatest variation exhibited in high-grade astrocytomas. Primary glioblastoma cell cultures and established glioblastoma cell lines also displayed some variability in connexin43 levels. In aggregate, our results anticipate that glioblastomas will have a varied bystander effect during HSV-tk gene therapy depending on the level of connexin43 expression.
authors.affiliation: Department of Cell Biology, University of Cincinnati, College of Medicine, Ohio, USA.
authors.forename: N
authors.initials: N
authors.lastname: Shinoura
authors.forename: L
authors.initials: L
authors.lastname: Chen
authors.forename: M A
authors.initials: MA
authors.lastname: Wani
authors.forename: Y G
authors.initials: YG
authors.lastname: Kim
authors.forename: J J
authors.initials: JJ
authors.lastname: Larson
authors.forename: R E
authors.initials: RE
authors.lastname: Warnick
authors.forename: M
authors.initials: M
authors.lastname: Simon
authors.forename: A G
authors.initials: AG
authors.lastname: Menon
authors.forename: W L
authors.initials: WL
authors.lastname: Bi
authors.forename: P J
authors.initials: PJ
authors.lastname: Stambrook
mesh_terms: D001254:Astrocytoma / Q000188:drug therapy*; D015152:Blotting, Northern; D001932:Brain Neoplasms / Q000188:drug therapy*; D018031:Connexin 43 / Q000235:genetics*; D015870:Gene Expression / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D011506:Proteins / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D018031:Connexin 43; D011506:Proteins; D012333:RNA, Messenger